3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
9
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Prostate Cancer Non-Metastatic
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Genital Diseases, Male
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
enzalutamide
2
cabazitaxel
2
Prednisone
2
Androgen Antagonists
2
fludrocortisone acetate
1
darolutamide
1
XRP6258
1
Radiosurgery
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Lenograstim
1
Hydrocortisone
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostate Cancer Metastatic
×
darolutamide
×
Clear all
NCT04916613
2026-04-28
GETUG-AFU 40
UNICANCER
Phase 3
Recruiting
300 enrolled